Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Presentation in november
View:
Post by Lesalpes29 on Oct 05, 2022 8:35am

Presentation in november

Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) BREAKING NEWS: Oncolytics Biotech Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting - Interim results from the phase 1/2 GOBLET study's pancreatic cancer cohort to be presented in a poster on November 11th and discussed during a key opinion leader webinar on November 14th at 10 a.m. ET -
Comment by cardu on Oct 05, 2022 9:22am
Hopefully, this could be the start of the plethora of positive news we've all been waiting for. Make the 4th quarter the one we'll all remember.
Comment by cardu on Oct 05, 2022 3:11pm
I notice the NR isn't on the ONC website.. Why?
Comment by Lesalpes29 on Oct 05, 2022 3:20pm
Good question. Can't see it anywhere!
Comment by Lesalpes29 on Oct 05, 2022 3:22pm
Saw it on stocktwits and ceo.ca.
Comment by Lesalpes29 on Oct 05, 2022 3:24pm
It's in oncolytics website.
Comment by jimsenior on Oct 05, 2022 3:24pm
Look under media, press releases. It is there.
Oncolytics Biotech Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities